Stock Information

• Reported Saturday, Arrowhead's Plozasiran Delivers 83% Median Triglyceride Reduction In Severe hypertriglyceridemia Patients With Zero Acute Pancreatitis Events Over Two-Year Open-Label Extension Study
  Mon, Mar 30, 2026 3:28 AM
• Arrowhead Plozasiran Data Supports Triglyceride Reduction And Valuation Upside Potential
  Sun, Mar 29, 2026 4:04 PM
• Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo
  Sat, Mar 28, 2026 2:30 PM
• SRPT Stock Surges on Promising Early Results From siRNA Programs
  Thu, Mar 26, 2026 5:14 PM
• Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market
  Thu, Mar 26, 2026 1:47 PM
• Arrowhead Pharmaceuticals: Transition Phase With Moderate Upside Ahead
  Thu, Mar 26, 2026 7:13 AM
• Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets
  Wed, Mar 25, 2026 5:10 PM
• AAR Foods Posts Upbeat Q3 Earnings, Joins Braze, Arm Holdings And Other Big Stocks Moving Higher On Wednesday
  Wed, Mar 25, 2026 2:32 PM
• Sarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout?
  Wed, Mar 25, 2026 1:44 PM
• HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $100 Price Target
  Wed, Mar 25, 2026 1:30 PM

Financial data not available